PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Blood thinner apixaban prevents strokes in patients with device-detected atrial fibrillation

2023-11-12
(Press-News.org) The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found. 

The oral anticoagulant medication, which helps to prevent dangerous blood clots by thinning the blood, reduced the risk of stroke and blood clotting by 37% and reduced fatal or disabling stroke by 49% in individuals with device-detected atrial fibrillation, also known as sub-clinical atrial fibrillation (SCAF). This condition is not easily detectable through standard tests like electrocardiograms, unlike clinical atrial fibrillation. 

The study was published on Nov. 12 in the New England Journal of Medicine (NEJM) and simultaneously presented at the American Heart Association Scientific Sessions by lead researcher Jeff Healey, a senior scientist at the Population Health Research Institute (PHRI), a joint research institute of McMaster University and Hamilton Health Sciences. 

Healey and a global team of researchers conducted the largest and longest-running study of apixaban for people with device-detected atrial fibrillation. The study involved more than 4,000 participants at 288 sites in 16 countries over eight years. 

“While we found an increase in major bleeding, this non-fatal bleeding is usually reversible and most patients recover from it,” says Healey, co-principal investigator (PI) of the study. 

“Considering how much more severe and life-altering the strokes prevented by apixaban are, compared to most cases of bleeding, our findings indicate that apixaban should be considered for patients with stroke risk factors who develop device-detected atrial fibrillation,” says Stuart Connolly, a PHRI senior scientist and chair of the study. 

Renato Lopes, co-PI of the study, cardiologist, and professor in the Department of Medicine at Duke University School of Medicine says, “Our findings can aid doctors in treating these patients, so they don’t suffer disabling and fatal strokes.” 

This global trial was an academic collaboration between the Duke Clinical Research Institute and PHRI, leading research institutes in the area of cardiology and clinical trials. In the rapidly evolving landscape of cardiac monitoring, Healey underscores the study’s far-reaching impact. 

“Our findings also have a broader significance,” Healey notes, “as we witness the increasing use of implanted and wearable cardiac monitors, along with consumer devices like the Apple Watch. A future where more at-risk individuals are identified and receive effective stroke prevention treatment is on the horizon.” 

The study was funded by the Canadian Institutes for Health Research, the Bristol-Myers Squibb-Pfizer Alliance, the Heart and Stroke Foundation of Canada, the Canadian Stroke Prevention Intervention Network (CSPIN), Hamilton Health Sciences, the Advancing Clinical Trials (ACT) Network and the Population Health Research Institute. 

END


ELSE PRESS RELEASES FROM THIS DATE:

New study finds genetic testing can effectively identify patients with family history of high cholesterol to prevent heart attack, stroke, and death

New study finds genetic testing can effectively identify patients with family history of high cholesterol to prevent heart attack, stroke, and death
2023-11-12
Familial hypercholesteremia (FH) is an inherited condition that affects about 1 in 250 people, and often shows no signs until they have a heart attack. For individuals with FH the lowering of “bad” cholesterol levels can’t be done by dietary or behavioral changes, the problem is in their genes, and targeted medications therapy is needed. Now, new research from the Intermountain Health in Salt Lake City has found that genetic screening can identify these patients and make them candidates for treatment that could prevent heart attack, stroke, and death. “Most of these patients already had tests that ...

New study finds genetic testing is effective in identifying patients with inherited risk of cardiomyopathy to improve quality of life and reduce deaths

New study finds genetic testing is effective in identifying patients with inherited risk of cardiomyopathy to improve quality of life and reduce deaths
2023-11-12
New research from Intermountain Health in Salt Lake City finds that genetic screening is effective in identifying patients who have a heart condition known as cardiomyopathy to improve their quality of life and reduce deaths. By undergoing genetic screening to identity those with the potentially-fatal heart condition, clinicians can more closely monitor them and use medical interventions, when necessary, that could improve the quality of these patients’ lives, and potentially save them, researchers say in a new study of more than 30,000 heart patients. “Our findings show that we’re ...

HSS research shows obesity is associated with worse flare symptoms and quality of life in people with early rheumatoid arthritis

2023-11-12
SAN DIEGO, CA, NOVEMBER 12, 2023 — A recent study from Hospital for Special Surgery (HSS) and others has found a correlation between obesity and more severe disease flare symptoms that negatively affect quality of life in patients with early rheumatoid arthritis (RA), a systemic, autoimmune, inflammatory disorder affecting multiple joints in the body. The study will be presented at ACR Convergence 2023, the annual meeting of the American College of Rheumatology. RA is usually treated with a combination of medications to relieve swelling and pain while regulating the immune ...

Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management

2023-11-11
About The Study: Self-monitoring and physician-guided titration of antihypertensive medications was associated with lower blood pressure during the first nine months postpartum than usual postnatal outpatient care in this randomized clinical trial involving 220 participants in the United Kingdom.  Authors: Paul Leeson, Ph.D., of the University of Oxford in Oxford, United Kingdom, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2023.21523) Editor’s ...

Cut salt, cut blood pressure

2023-11-11
  ·  High blood pressure is the leading cause of morbidity and mortality ·  Losing one teaspoon of salt a day results in systolic blood pressure decline comparable to effect achieved with drugs ·  First study to show people already on blood pressure medication could further lower their blood pressure by reducing sodium Chicago --- Nearly everyone can lower their blood pressure, even people currently on blood pressure-reducing drugs, by lowering their sodium intake, reports a new study from Northwestern Medicine, Vanderbilt University Medical Center and the University of Alabama at Birmingham. “In the study, ...

Effect of dietary sodium on blood pressure

2023-11-11
About The Study: Dietary sodium reduction significantly lowered blood pressure in the majority of middle-aged to elderly adults in this study including 213 participants. The decline in blood pressure from a high- to low-sodium diet was independent of hypertension status and antihypertensive medication use, was generally consistent across subgroups, and did not result in excess adverse events.  Authors: Deepak K. Gupta, M.D., M.S.C.I., of the Vanderbilt University Medical Center in Nashville, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2023.23651) Editor’s ...

Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure

2023-11-11
About The Study: This randomized clinical trial found that in patients with advanced heart failure treated with a fully magnetically levitated left ventricular assist device, avoidance of aspirin as part of an antithrombotic regimen, which includes a vitamin K antagonist, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events.  Authors: Mandeep R. Mehra, M.D., M.Sc., of Brigham and Women’s Hospital and Harvard Medical School in Boston, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link ...

New AHA Center for Telehealthâ„¢ will increase access to quality health care and improve delivery

2023-11-11
According to the American Medical Association, approximately 25% of all patients used telehealth services during the last year, exceeding the 5% who accessed their care this way before the pandemic.[1] The American Heart Association (AHA) Center for Telehealth, unveiled today, recognizes the critical role telehealth can play as a solution to close gaps in health care access, particularly in rural and underserved areas, and deliver quality care to populations that have little to no access to traditional ...

New study finds coronary calcium scores highly effective in identifying heart disease in people without any known risk factors

New study finds coronary calcium scores highly effective in identifying heart disease in people without any known risk factors
2023-11-11
While high cholesterol, high blood pressure, diabetes and smoking are well known heart disease risks, not everyone who has a heart attack has them. In fact, previous research has shown that 14% to 27% of heart attack patients have none of these risk factors. Now, a new study from researchers at Intermountain Health in Salt Lake City finds that these patients had one thing in common: they all tended to have high levels of coronary calcium. Results of the new Intermountain study show that scans that detect this kind of plaque buildup should be considered as ...

Understanding the stressed, depressed, adolescent brain

2023-11-11
WASHINGTON — Advanced brain imaging techniques reveal how adolescent brain development influences, and is influenced by, factors including chronic stress and mood disorders. The findings will be presented on Monday, November 13, 11:15 a.m. – 12:15 p.m. EST at Neuroscience 2023, the annual meeting of the Society for Neuroscience and the world’s largest source of emerging news about brain science and health. Adolescence is a time of social, biological, and emotional changes, as well as continued brain development. Mental health among teenagers was already declining before the COVID-19 pandemic, according to data from the Centers for Disease Control ...

LAST 30 PRESS RELEASES:

Scientists uncover key to decoupling economic growth from pollution in developing countries

Frailty fuels gut imbalance and post-surgery gastrointestinal risks

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

Training to improve memory

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

[Press-News.org] Blood thinner apixaban prevents strokes in patients with device-detected atrial fibrillation